Subscribe: Nature Reviews Clinical Oncology - Issue - nature.com science feeds
http://www.nature.com/ncponc/current_issue/rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
cancer  cell  clinical  imaging  immunotherapy  lung cancer  macrophages  molecular  new  patients  tams  therapy  treatment  tumour macrophages  tumour 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Nature Reviews Clinical Oncology - Issue - nature.com science feeds

Nature Reviews Clinical Oncology



Nature Reviews Clinical Oncology provides physicians and academics with authoritative and topical discussions of key developments in the field.



 



Lung cancer: Tracing tumour evolution

2017-05-16

One key hypothesis proposed to explain the resistance of tumours to otherwise effective therapies is the existence of an evolution process whereby cancer cells harbouring or acquiring resistance mechanisms escape selective pressure. Results of several studies have confirmed this hypothesis, which is reinforced by the



Immunotherapy: Nivolumab keeps HCC in check and opens avenues for checkmate

2017-05-09

Annually, ∼750,000 new cases of hepatocellular carcinoma (HCC) are diagnosed worldwide, mostly at an advanced stage, with dismal outcomes. Sorafenib, the only approved systemic therapy for advanced-stage HCC, is of limited benefit, and no standard second-line therapy exists. New data indicate the therapeutic potential of



Lung cancer: KEYNOTE-001 — combo improves melody

2017-06-13

Immunotherapy-based approaches have become a treatment option for patients with non-small-cell lung cancer (NSCLC). Importantly, evidence from preclinical studies suggests that radiotherapy stimulates an antitumour immune response. In order to investigate this hypothesis, Percy Lee, Narek Shaverdian and collaborators undertook a secondary analysis of the



Immunotherapy: Exploiting PD-1 on TAMs for tumour cell kill

2017-06-13

In patients with cancer, the presence of tumour-associated macrophages (TAMs) portends a poor prognosis. Macrophages have been shown to express PD-1 in the context of pathogen infection; thus, the possibility that TAMs might also express PD-1 in the tumour microenvironment was explored in a new



Prostate cancer: AR mutations in plasma DNA indicate outcomes

2017-05-23

An urgent need exists for predictive biomarkers that can be sampled noninvasively in men with prostate cancer. Towards this goal, an analysis of androgen receptor (AR) gene status was conducted using plasma DNA samples from androgen-deprivation therapy (ADT)-naive patients receiving ADT with either



Haematological cancer: Pembrolizumab is effective in multiple myeloma

2017-05-23

Newly published data from a phase II study involving patients with relapsed and/or refractory multiple myeloma (RRMM) indicate that the anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab can enhance the efficacy of pomalidomide plus dexamethasone. A total of 48 patients were included in this



Skin cancer: Mutational landscape of melanoma revealed

2017-05-23

Most cutaneous melanomas have a distinct, UV-radiation-induced mutational signature, which is dominated by C>T nucleotide transitions. However, the mutational landscape of melanomas ocurring at ocular, acral, and mucosal surfaces remains less well understood. Now, a high-coverage whole-genome sequencing study has revealed that the noncutaneous subtypes



Immunotherapy: Macrophages hijack anti-PD-1 therapy

2017-05-31

Anti-PD-1 antibodies (αPD-1) can provide long-term clinical benefit, but only for a minority of patients with cancer; our understanding of the mechanisms of response or resistance to these agents is limited. Mikael Pittet and co-workers sought to address this knowledge gap by studying the pharmacokinetics



Targeted therapies: J-ALEX hints at new first-line in NSCLC

2017-05-31

A better understanding of the genetic landscape of non-small-cell lung cancer (NSCLC) has improved the management of this disease. Crizotinib is the standard first-line therapy for patients with ALK rearrangements. Upon disease progression, second-generation ALK inhibitors are available, such as alectinib that targets certain



In the news: From ASCO 2017

2017-06-20

Between the 2nd and 6th of June, more than 30,000 delegates descended on Chicago for the 53rd ASCO meeting. This meeting is an annual forum for discussion of recent clinical advances, which are testament to the dedication of the oncology community, not least the critical



Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?

2017-04-25

Adjuvant ipilimumab is associated with an 11% improvement in 5-year overall survival in patients with high-risk melanoma, but at the cost of considerable toxicity, with half of patients discontinuing treatment owing to adverse events. An analysis of quality-of-life (QoL) outcomes, however, showed little impact of adverse effects of this treatment on QoL, which is puzzling.



Gynaecological cancer: Novel molecular subtypes of cervical cancer — potential clinical consequences

2017-04-11

The Cancer Genome Atlas Research Network recently published the most comprehensive, multi-omic molecular characterization of cervical cancers performed to date. The data reveal novel disease subtypes, and provide new insights into the aetiology and pathogenesis of cervical cancer. Importantly, the information obtained has potentially major clinical implications.



Tumour-associated macrophages as treatment targets in oncology

2017-01-24

Macrophages are crucial drivers of tumour-promoting inflammation. Tumour-associated macrophages (TAMs) contribute to tumour progression at different levels: by promoting genetic instability, nurturing cancer stem cells, supporting metastasis, and taming protective adaptive immunity. TAMs can exert a dual, yin–yang influence on the effectiveness of cytoreductive therapies



Proteasome inhibitors in cancer therapy

2017-01-24

The ubiquitin proteasome pathway was discovered in the 1980s to be a central component of the cellular protein-degradation machinery with essential functions in homeostasis, which include preventing the accumulation of misfolded or deleterious proteins. Cancer cells produce proteins that promote both cell survival and proliferation,



Advances in the molecular genetics of gliomas — implications for classification and therapy

2016-12-29

Genome-wide molecular-profiling studies have revealed the characteristic genetic alterations and epigenetic profiles associated with different types of gliomas. These molecular characteristics can be used to refine glioma classification, to improve prediction of patient outcomes, and to guide individualized treatment. Thus, the WHO Classification of Tumours



Independent imaging biomarkers do not exist

2017-06-13

Link to original article O'Connor, J. P. B. et al. Imaging biomarker roadmap for cancer studies. Nat. Rev. Clin. Oncol.14, 169–186 (2017).In their Consensus Statement published in the March 2017 issue of this journal (Imaging biomarker roadmap for cancer



Imaging biomarkers exist and they underpin clinical decision-making

2017-06-13

We thank Dr Burke for his interest (Independent imaging biomarkers do not exist. Nat. Rev. Clin. Oncol.http://dx.doi.org/10.1038.nrclinonc.2016.162-c1; 2017) in the international consensus statement on 'imaging biomarker' translation that we led on behalf of Cancer Research UK (CRUK) and the European Organisation